Garraway, L. A. & Lander, E. S. Lessons from the cancer genome. Cell 153, 17–37 (2013).
CAS PubMed Article Google Scholar
Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).
CAS PubMed PubMed Central Article Google Scholar
Hahn, W. C. et al. An expanded universe of cancer targets. Cell 184, 1142–1155 (2021).
CAS PubMed PubMed Central Article Google Scholar
McCoach, C. E. & Bivona, T. G. Engineering multidimensional evolutionary forces to combat cancer. Cancer Discov. 9, 587–604 (2019).
CAS PubMed PubMed Central Article Google Scholar
Marine, J.-C., Dawson, S.-J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20, 743–756 (2020).
CAS PubMed Article Google Scholar
Garraway, L. A. Genomics-driven oncology: framework for an emerging paradigm. J. Clin. Oncol. 31, 1806–1814 (2013).
Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495–501 (2014).
CAS PubMed PubMed Central Article Google Scholar
Byrne, A. T. et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat. Rev. Cancer 17, 254–268 (2017).
CAS PubMed Article Google Scholar
Stripecke, R. et al. Innovations, challenges, and minimal information for standardization of humanized mice. EMBO Mol. Med. 12, e8662 (2020).
CAS PubMed PubMed Central Article Google Scholar
De Palma, M., Biziato, D. & Petrova, T. V. Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer 17, 457–474 (2017).
Bailey, C. et al. Tracking cancer evolution through the disease course. Cancer Discov. 11, 916–932 (2021).
CAS PubMed PubMed Central Article Google Scholar
Aparicio, S., Hidalgo, M. & Kung, A. L. Examining the utility of patient-derived xenograft mouse models. Nat. Rev. Cancer 15, 311–316 (2015).
CAS PubMed Article Google Scholar
Avolio, M. & Trusolino, L. Rational treatment of metastatic colorectal cancer: a reverse tale of men, mice, and culture dishes. Cancer Discov. 11, 1644–1660 (2021).
CAS PubMed Article Google Scholar
Ben-David, U. et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat. Genet. 49, 1567–1575 (2017).
CAS PubMed PubMed Central Article Google Scholar
Woo, X. Y. et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat. Genet. 53, 86–99 (2021).
CAS PubMed PubMed Central Article Google Scholar
Hoge, A. C. H. et al. DNA-based copy number analysis confirms genomic evolution of PDX models. NPJ Precis. Oncol. 6, 30 (2022).
CAS PubMed PubMed Central Article Google Scholar
Sun, H. et al. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nat. Commun. 12, 5086 (2021).
CAS PubMed PubMed Central Article Google Scholar
Schmitt, M. W., Loeb, L. A. & Salk, J. J. The influence of subclonal resistance mutations on targeted cancer therapy. Nat. Rev. Clin. Oncol. 13, 335–347 (2016).
CAS PubMed Article Google Scholar
Izumchenko, E. et al. Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors. Ann. Oncol. 28, 2595–2605 (2017).
CAS PubMed PubMed Central Article Google Scholar
Hidalgo, M. et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 10, 1311–1316 (2011).
CAS PubMed PubMed Central Article Google Scholar
Eirew, P. et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518, 422–426 (2015).
CAS PubMed Article Google Scholar
Salehi, S. et al. Clonal fitness inferred from time-series modelling of single-cell cancer genomes. Nature 595, 585–590 (2021).
CAS PubMed PubMed Central Article Google Scholar
Dang, H. X. et al. The clonal evolution of metastatic colorectal cancer. Sci. Adv. 6, eaay9691 (2020).
CAS PubMed PubMed Central Article Google Scholar
Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339, 543–548 (2013).
CAS PubMed Article Google Scholar
Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010).
CAS PubMed PubMed Central Article Google Scholar
Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262–269 (2016).
CAS PubMed PubMed Central Article Google Scholar
Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576–582 (2021).
CAS PubMed PubMed Central Article Google Scholar
Fakih, M. G. et al. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin. Cancer Res. 16, 3786–3794 (2010).
CAS PubMed PubMed Central Article Google Scholar
Meng, Y. et al. Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer. Ann. Palliat. Med. 10, 11255–11264 (2021).
Cleary, J. M. et al. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest. New Drugs 32, 937–945 (2014).
CAS PubMed Article Google Scholar
Vlahovic, G. et al. A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. Invest. New Drugs 32, 976–984 (2014).
CAS PubMed Article Google Scholar
Rambow, F. et al. Toward minimal residual disease-directed therapy in melanoma. Cell 174, 843–855 (2018).
CAS PubMed Article Google Scholar
Marin-Bejar, O. et al. Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer Cell 39, 1135–1149 (2021).
CAS PubMed Article Google Scholar
Vendramin, R. et al. Activation of the integrated stress response confers vulnerability to mitoribosome-targeting antibiotics in melanoma. J. Exp. Med. 218, e20210571 (2021).
CAS PubMed PubMed Central Article Google Scholar
Buczacki, S. J. A. et al. Intestinal label-retaining cells are secretory precursors expressing Lgr5. Nature 495, 65–69 (2013).
CAS PubMed Article Google Scholar
Basak, O. et al. Induced quiescence of Lgr5+ stem cells in intestinal organoids enables differentiation of hormone-producing enteroendocrine cells. Cell Stem Cell 20, 177–190 (2017).
CAS PubMed Article Google Scholar
Barriga, F. M. et al. Mex3a marks a slowly dividing subpopulation of Lgr5+ intestinal stem cells. Cell Stem Cell 20, 801–816 (2017).
CAS PubMed PubMed Central Article Google Scholar
Lupo, B. et al. Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype. Sci. Transl Med. 12, eaax8313 (2020).
留言 (0)